Reports Q2 revenue $44.2M, consensus $42.5M. “Strong growth in our spatial biology business and continued durability in our nCounter business helped us generate record revenue during the second quarter,” said Brad Gray, President and CEO of NanoString. “We expect to continue to benefit from substantial CosMx instrument order backlog through the back half of the year and into 2024, providing visibility into revenue growth and anticipated reductions in our working capital requirements, cash burn and operating loss.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NSTG:
- Biotech Alert: Searches spiking for these stocks today
- Court permits NanoString counterclaim in 10x Genomics, Harvard litigation
- NanoString backs FY23 revenue view $175M-$185M, consensus $179.13M
- NanoString preliminary Q2 revenue $44M, consensus $41.38M
- NanoString assumed with an Overweight at JPMorgan